BioSpace News Archive

IceCure Medical Ltd. announced that it will release its full year financial and operational results for the twelve months ended December 31, 2022, prior to the market open on Wednesday, March 29, 2023, and will host a conference call at 10:00 a.m. ET to discuss the results and corporate developments.

Vaxxinity, Inc. today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401.

Synchron today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB).

FORE Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labelled somatostatin analogue therapy.

Cerevance today announced plans to present two symposium oral presentations and a poster presentation at the upcoming AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place in Gothenburg, Sweden, March 28 – April 1, 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479.

CoImmune, Inc. announced it has exercised its option to obtain an exclusive license in the CD19-targeted, allogeneic cell therapy field to IL-18 Armored Chimeric Antigen Receptor technology under a prior agreement with Memorial Sloan Kettering Cancer Center.

QSAM Biosciences, Inc. is pleased to announce that it has been invited to provide updates on its clinical trial evaluating CycloSam® for the treatment of metastatic bone cancer at the Emerging Growth Conference on Wednesday, March 22, 2023, at 2:50 PM EST.

Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19.